Complementing the company's in - house Crispr programme, the technology will identify and validate new targets in
preclinical models across a range of disease areas.
Not exact matches
NeuroPhage has accumulated extensive
preclinical data on this candidate, demonstrating its efficacy
across disease
models of Alzheimer's and Parkinson's disease, tauopathies and other related diseases characterized by aggregation of amyloid beta, tau, and alpha - synuclein proteins.
The goal of this Center of Excellence is to better define thrombus development in patients with cancer, test the efficacy of novel therapies, develop new
preclinical models, and create and expand biorepositories to provide a valuable resource to researchers
across Cleveland Clinic.